clinical trial · NCT03149549
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Solid Tumor, AdultBreast CancerNon Small Cell Lung CancerHead and Neck CancerOvarian CancerCX-2009
brief summary
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc
started
Jun 1, 2017
primary completion
Sep 10, 2020
completion
Sep 10, 2020
last updated
Jan 5, 2024
official title
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol